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Abstract  Hepatocellular  carcinoma  (HCC)  is  one  of  the  leading  causes  of  neoplastic  morbidity
and mortality  worldwide,  and  despite  recent  treatment  advances,  the  prognosis  remains  dismal,
with a  5-year  mortality  rate  of  85%.
The surveillance  and  timely  diagnosis  is  therefore  of  crucial  importance  in  order  to  improve
survival rates  and  alleviate  the  health  burden  imposed  by  the  HCC.
Previously,  HCC  diagnosis  warranted  liver  biopsy,  an  invasive  process  with  limited  diagnostic
accuracy. In  the  past  15  years,  HCC  diagnosis  based  solely  on  imaging  criteria  was  accepted
by all  the  major  national  and  international  guidelines,  and  is  now  widely  employed  across  the
globe.
Current European  guidelines  for  the  HCC  diagnosis  support  the  use  of  both  dynamic  contrasted
computer tomography  as  well  as  magnetic  resonance  imaging  for  the  non-invasive  diagnosis
of HCC  for  nodules  >1  cm  in  a  cirrhotic  liver.  The  non-invasive  diagnosis  of  HCC  depends  on
radiological  hallmarks,  such  as  homogeneous  contrast  uptake  during  the  arterial  phase  and
wash-out during  the  venous  and  late  phases,  but  while  such  tumoral  behaviour  is  frequent
in nodules  >2  cm,  high-end  equipment  and  superior  expertise  is  often  needed  for  the  correct
diagnosis  of  early  HCC.
Nevertheless,  the  accuracy  of  imaging  techniques  for  the  diagnosis  of  HCC  is  permanently
improving,  and  supports  the  progressively  reduced  need  for  liver  biopsy  during  liver  nodule
workout  in  a  cirrhotic  liver.
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Diagnóstico  Imagiológico  de  Doenc¸as Gastrointestinais  --  Critérios  Diagnósticos  do
Carcinoma  Hepatocelular
Resumo  O  carcinoma  hepatocelular  (CHC)  é  uma  das  principais  causas  de  morbi-mortalidade
a nível  mundial,  e  apesar  de  avanc¸os  no  tratamento,  o  prognóstico  é  sombrio,  com  uma  mor-
talidade aos  5  anos  de  85%.
Assim,  reveste-se  de  particular  importância  a  vigilância  e  diagnóstico  precoce  do  CHC,  de
forma a  alterar  substancialmente  as  taxas  de  sobrevida  desta  neoplasia.
Previamente,  o  diagnóstico  do  CHC  exigia  a  realizac¸ão  de  uma  biópsia  hepática,  uma  técnica
invasiva  com  acuidade  diagnóstica  limitada.  Nos  últimos  15  anos,  o  diagnóstico  baseado  em  téc-
nicas de  imagem  foi  sendo  progressivamente  aceite  pelas  principais  recomendac¸ões  nacionais
e internacionais,  e  é  agora  extensamente  aplicado  em  todo  o  mundo.
As recomendac¸ões  europeias  mais  recentes  para  o  diagnóstico  do  CHC  aceitam  a  utilizac¸ão  de
tomograﬁa  computorizada  contrastada  e  ressonância  magnética  contrastada  para  o  diagnóstico
não invasivo  de  CHC  em  nódulos  >1  cm  no  fígado  cirrótico.  Este  diagnóstico  depende  da  presenc¸a
de alterac¸ões  imagiológicas  típicas,  como  a  hipercaptac¸ão  homogénea  de  contraste  na  fase
arterial e  o  wash-out  nas  fases  portal  e  tardia,  características  frequentes  em  nódulos  >2  cm,
mas de  difícil  identiﬁcac¸ão  em  CHC  de  dimensões  reduzidas.
Em conclusão,  as  técnicas  imagiológicas  para  o  diagnóstico  do  CHC  apresentam  uma  acuidade
diagnóstica  progressivamente  mais  elevada,  e  permitirão  reduzir  signiﬁcativamente  a  necessi-
dade de  biópsia  hepática  durante  a  abordagem  de  nódulos  hepáticos  num  fígado  cirrótico.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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t. Hepatocellular carcinoma epidemiology
epatocellular  carcinoma  (HCC)  is  the  third  most  common
umour  worldwide  and  the  second  leading  cause  of  cancer-
elated  deaths.1 The  overall  5-year  survival  of  patients  with
CC  is  15%,  indicating  its  generally  poor  prognosis.  However,
0%  of  patients  who  are  diagnosed  with  the  disease  localized
o  the  liver  have  improved  5-year  survival  rates  of  30%.1
Cirrhosis  is  the  most  important  risk  factor  for  HCC.  More
han  80%  of  the  cases  of  HCC  occur  in  the  setting  of  cirrhosis,
nd  in  these  patients,  HCC  is  the  leading  cause  of  death.2
mportantly,  up  to  20%  of  patients  with  HCC  in  the  setting  of
BV  infection  develop  without  evidence  of  cirrhosis.  Among
atients  with  cirrhosis,  alcohol,  tobacco,  obesity,  diabetes,
lder  age,  and  male  gender  are  associated  with  an  increase
n  the  risk  for  the  development  of  HCC.1
Moreover,  the  risk  of  HCC  in  cirrhotic  patients  depends
n  the  aetiology  of  cirrhosis;  2--8%  per  year  in  hepatitis  C-
elated  liver  cirrhosis,  2.5%  per  year  in  chronic  hepatitis  B-
elated  cirrhosis,  and  <2%  in  primary  biliary  and  autoimmune
irrhosis.3,4
. HCC surveillance
ational  and  society  guidelines  recommend  surveillance
rogrammes  for  HCC5--8 on  the  basis  of  reduced  mortality9,10
nd  cost-effectiveness.11 Current  European  Association  for
he  Study  of  the  Liver  (EASL)  guidelines  support  HCC  surveil-
ance  in  cirrhotic  patients  Child--Pugh  A  and  B,  Child--Pugh
 included  in  transplant  lists,  non-cirrhotic  HBV  carri-
rs  with  active  hepatitis  or  family  history  of  HCC,  and
d
2
ton-cirrhotic  patients  with  chronic  hepatitis  C  and  advanced
iver  ﬁbrosis.5
Liver  ultrasound  (US)  is  the  diagnostic  procedure  of
hoice  across  all  major  guidelines,12 with  a  pooled  sensi-
ivity  for  HCC  of  almost  95%  in  a  recent  meta-analysis.13 In
xperienced  hands,  US  allows  for  the  detection  of  diminu-
ive  nodules  (Fig.  1);  in  a  Japanese  study,  the  average  size
f  the  detected  malignancy  was  1.6  ±  0.6  cm,  and  remark-
bly,  the  tumour  was  larger  than  3  cm  in  only  2%  of  the
atients.14 Despite  being  operator-dependent,  with  difﬁcult
dentiﬁcation  of  a  focal  malignant  nodule  in  a  cirrhotic  liver,
S  is  affordable,  easily  accepted  by  patients  and  with  no
ssociated  risks,  allowing  for  its  progressively  wider  use.
herefore,  in  patients  where  surveillance  is  warranted,  liver
S  should  be  performed  every  6  months.5
The  use  of  serological  markers,  such  as  alpha-fetoprotein
AFP),  des-gamma-carboxy  prothrombin  (DCP)  and  glyco-
ylated  AFP  (AFP-L3),  although  incorporated  in  Japanese7
nd  Asian-Paciﬁc,8 are  not  presently  supported  in  the  EASL
uidelines  for  HCC  surveillance.5 AFP  in  the  surveillance  set-
ing  has  been  shown  to  improve  HCC  detection  compared
o  US  alone  in  just  6--8%  of  the  patients,15 as  only  20%  of
arly-HCC  present  with  elevated  AFP  serum  levels.  Addi-
ionally,  AFP  leads  as  well  to  an  increase  in  the  number
f  false  positives,  and  consequently,  in  the  cost  for  HCC
iagnosis.5,6
Dimension  is  of  crucial  importance  in  liver  nodules,  as  less
han  half  the  nodules  <1  cm  in  a  cirrhotic  liver  correspond
o  HCC,16,17 but  more  than  90%  of  nodules  >3  cm  lead  to  the
iagnosis  of  HCC.18 The  rate  of  HCC  in  nodules  between  1  and
 cm  is  66%  and  almost  80%  in  nodules  2--3  cm.2,19 Therefore,
he  current  challenge  in  HCC  diagnosis  is  the  detection  and
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nFigure  1  Small  hypoechoic  nodule  in  a  cirrhotic  liver  corre-
sponding  to  an  HCC  (arrow).
characterization  of  nodules  larger  than  1  but  smaller  than
3  cm.
In cirrhotic  patients,  nodules  <1  cm  detected  by  US  should
prompt  a  recall  within  4  months,  to  assess  either  size
or  character  changes,5 in  order  to  maximize  the  surveil-
lance  effectiveness,  allowing  for  the  diagnosis  of  early-HCC
(<2  cm).  Such  lesions  should  be  evaluated  every  4  months
for  the  ﬁrst  year,  and  if  stable,  every  6  months  thereafter.5
Nodules  >1  cm  should  be  considered  abnormal  until  oth-
erwise  proven,  and  warrant  further  investigation,  either  by
guided  biopsy  or  non-invasive  diagnostic  modalities.5,16
3. HCC diagnosis
Up  until  2000,  the  diagnosis  of  HCC  was  conﬁrmed  only  by
histology  ﬁndings  in  a  liver  biopsy.20 However,  percutaneous
liver  biopsy  has  a  number  of  contraindications,  such  as  asci-
tis,  impaired  hemostasis  and  antithrombotic  medication.21
Moreover,  it  is  an  invasive  technique,  with  an  associated
risk  of  complications,  the  most  frequent  being  pain  and
anxiety  (up  to  84%),2,21 while  serious  side  effects,  such  as
bleeding,  pneumothorax,  tumour  seeding,  perforation  and
sepsis,  occur  in  up  to  1%  of  patients22;  there  is  mortal-
ity  rate  for  liver  biopsy,  although  exceedingly  low  (<9  in
10,000).21,22 Lastly,  diagnostic  accuracy  of  liver  biopsy  is
limited  by  sampling  error,  as  well  as  the  uncertainty  in  the
crucial  histological  differentiation  between  advanced  dys-
plastic  nodules  and  well-differentiated  HCC,  leading  to  both
false  negative  results  (up  to  40%  in  HCC  ≤2  cm2,23)  as  well
as  false  positive  results.2
The  2001  EASL  guidelines  accepted  for  the  ﬁrst  time
non-invasive  criteria  for  the  diagnosis  of  HCC  in  nodules
>2  cm  in  a  cirrhotic  patient,16 when  coincident  and  sug-
gestive  ﬁndings  of  HCC  were  found  in  at  least  2  imaging
techniques  --  contrast-enhanced  ultrasound  (CEUS),  dynamic
CT,  MRI  or  angiography.24--26 Non-invasive  diagnosis  of  HCC
has  been  subsequently  validated  in  prospective  studies,2
v
r
p
m155
nd  is  currently  accepted  by  European,5 north-American,6
sia-paciﬁc8 and  Japanese7 HCC  diagnosis  guidelines.
Tumour  angiogenesis  is  a  key  feature  for  HCC  growth  as
ell  as  metastatic  potential,27 and  a  possible  target  for
ntineoplastic  therapy28 but  it  is  also  a  critical  malignant
haracteristic  allowing  for  its  non-invasive  diagnosis.29
During  the  progression  from  dysplastic  nodule  to  well  dif-
erentiated  and  particularly  to  poorly  differentiated  HCC,
umour  angiogenesis  leads  to  newly  formed,  tortuous,  exces-
ively  branched  and  short  vessels,  in  a highly  disorganized
rchitecture.27,30 This  angiogenesis  is  driven  predominantly
hrough  the  formation  of  unpaired  arteries,  with  the  sup-
lantation  and  eventual  obliteration  of  intratumoral  portal
racts.29 As  such,  whereas  normal  liver  cells  and  pre-
alignant  dysplastic  nodules  are  perfused  through  portal
ranches,31 HCC  blood  supply  is  delivered  through  newly
ormed  arteries.29,31
Therefore,  the  diagnosis  of  HCC  using  imaging  tech-
iques  requires  the  use  of  contrasting  agents  for  identifying
eoplastic  vascularization  characteristics.  A  typical  HCC
ascular  pattern,  similar  across  the  different  imaging  modal-
ties,  has  been  deﬁned  as  the  presence  of  homogeneous
yperenhancement  in  the  arterial  phase  followed  by  wash
ut  in  the  venous  or  late  phase.32
The  use  of  dynamic  techniques  with  contrast  was  vali-
ated  almost  a  decade  ago,2 and  current  contrast-enhanced
odalities  include  CEUS,  dynamic  CT  and  dynamic  MRI.
.  CEUS
EUS,  using  microbubble  intravascular  contrast  agents  such
s  sulfur  hexaﬂuoride  with  a  phospholipid  shell  (Sonovue®),
as  shown  to  be  a  useful  diagnostic  technique  for  HCC  in  the
etting  of  cirrhosis;  the  typical  pattern  of  arterial  hyper-
nhancement  and  wash  out  in  the  portal  and  late  phases
orresponds  to  HCC  in  97%  of  the  patients  (Fig.  2).32--34 It
as  included  in  the  2001  EASL  Guidelines16 and  in  the  2005
ASLD  guidelines35 in  the  diagnostic  algorithm  of  HCC  in  the
irrhotic  liver,  as  well  as  being  incorporated  in  the  2010
apanese  guidelines  for  the  management  of  hepatocellular
arcinoma.7
In  2010,  however,  a  study  by  Villana  et  al.  in  a  subset
f  21  cirrhotic  patients  with  intrahepatic  cholangiocarci-
oma  (ICC),  only  11  patients  (52.4%)  presented  with  the
ypical  peripheral  rim  arterial  enhancement  of  ICC  dur-
ng  CEUS,  while  in  10  (47.6%)  of  these  patients,  arterial
yperenhancement  was  homogeneous,  suggestive  of  HCC.36
his  study  highlighted  the  likely  substantial  incidence  of
ncorrect  diagnosis  of  HCC  in  patients  with  ICC,  and  con-
rasted  with  the  contrasted  MRI  results,  where  only  two
atients  (9.5%)  presented  with  homogeneous  hyperenhance-
ent  during  the  arterial  phase.  Recently,  Li  et  al.  found  that
8.8%  (11  out  of  16)  of  the  ICC  in  patients  with  cirrhosis
ill  show  imaging  characteristics  of  HCC  in  CEUS,  and  such
ehaviour  occurs  more  frequently  than  in  patients  with  a
on-cirrhotic  liver  (six  out  of  23;  26.1%).37 The  clinical  rele-
ance  of  correct  differential  diagnosis  between  HCC  and  ICC
ests  on  the  increasing  incidence  of  the  latter,38 the  overlap-
ing  risk  factors38 and  the  vastly  different  approaches  and
anagement  of  both  malignancies.5,39
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cFigure  2  HCC  in  a  cirrhotic  liver  during  CEUS  (arrow
As  a  result,  CEUS  using  Sonovue® contrast  is  no  longer
dvocated  in  current  European  guidelines,  and  non-invasive
iagnosis  of  HCC  is  based  on  contrasted  CT  or  MRI  imaging
tudies  only.5 Japanese  guidelines  advocate  the  use  of  CEUS
s  a  ﬁrst  line  procedure  for  the  non-invasive  diagnosis  of
CC,  using  a  novel  contrasting  agent,  Sonazoid®.7
Unlike  Sonovue®,  Sonazoid® (perﬂuorobutane  with  a
hospholipid  shell:  hydrogenated  egg  phosphatidyl  serine),
navailable  in  Europe,  is  phagocytozed  by  Kupffer  cells,  and
xhibits  also  a  postvascular  (or  Kupffer)  phase.7,32 This  phase
s  crucial  for  the  characterization  of  HCC,  as  most  HCC  show
 decrease  in  absence  of  Sonazoid® uptake,  whereas  dys-
lastic  nodules  and  early  HCC  present  the  same  rate  of
ptake  as  the  surrounding  liver  parenchyma.7 Recent  studies
ith  Sonazoid® are  promising,40,41 and  its  use  is  maintained
nd  reinforced  in  the  2014  update  of  the  Japanese  HCC
uidelines,42 but  western  studies  are  needed  in  order  to
alidate  its  applicability  in  Europe  and  the  United  States.
. Dynamic CT and MRI
n  2005,  the  concept  of  ‘‘Radiological  hallmark  of  HCC’’,
ommon  to  both  dynamic  CT  and  MRI,  was  deﬁned  by  experts
nd  included  in  both  EASL  and  AASLD  guidelines,  and  it  con-
ists  of  homogeneous  contrast  uptake  during  the  arterial
hase  and  washout  during  the  venous/late  phases.5,35
Multidetector  4-phase  dynamic  CT  uses  iodine-based
ontrast  (1.5  mL/kg  body  weight,  corresponding  to  600  mg
odine/kg,  at  a  rate  of  4.5  mL/s)  with  superior  time  reso-
ution  and  faster  image  acquisition.43 Images  are  obtained
uring  the  precontrast,  hepatic  arterial  (25--40  s after  con-
rast  administration),  hepatic  venous  (70  s  after  contrast
dministration),  and  delayed  phase  (180--200  s  after  con-
rast  administration).  After  180--200  s,  the  vascular  and
xtracellular  contrast  medium  concentrations  reach  equilib-
ium  about  200  s  after  infusion  --  this  time  point  is  called  the
quilibrium  or  parenchymal  phase.7,12,44 During  this  phase,
 pseudocapsule  may  be  observed,  especially  in  cases  of
ell-differentiated  HCC.45,46
Dynamic  MRI,  using  gadolinium-based  contrast
0.1  mL/kg  body  weight,  corresponding  to  0.05  mmol
adobenate  dimeglumine/kg,  at  a  rate  of  2  mL/s),  follows
he  same  sequence  of  dynamic  CT  in  regards  to  phase  timing
nd  contrast  enhancement.  Recently,  a  new  hepatocyte-
peciﬁc  contrast  agent  for  MRI,  Gd-EOB-DTPA  (gadoxetate
odium),  was  developed,  exhibiting  a  post-vascular  phase,
imilar  to  the  Sonazoid® Kupffer  phase.7,47 Where  Son-
zoid  was  phagocytozed  by  Kupffer  cells,  Gd-EOB-DTPA  is
a
e
t
nrterial  phase  (a),  portal  phase  (b)  and  late  phase  (c).
bsorbed  by  hepatocytes  and  excreted  both  through  the
idney  and  the  bile  ducts.  This  results  in  a homogeneous
iver  enhancing  (hyperintensity  in  T1-weighted  images)
0--20  min  after  intravenous  contrast  administration.  There
s  no  contrast  uptake  by  malignant  lesions,  presenting
herefore  as  hypointense  during  the  hepatobiliary  phase.7,12
. Diagnostic criteria
n  the  presence  of  a  nodule  1--2  cm  in  a  cirrhotic  liver,  radio-
ogical  hallmarks  of  HCC  are  warranted  in  both  4-phase  CT
Fig.  3) and  dynamic  contrasted  MRI  (Fig.  4)  for  the  non-
nvasive  diagnosis  of  HCC.5
Focal  liver  lesions  in  a  cirrhotic  liver  are  overwhelm-
ngly  hepatocellular  adenomas  or  HCC,  and  the  differential
iagnosis  of  these  lesions  in  the  cirrhotic  setting  is  limited
-  regenerative  nodules,  cholangiocellular  carcinomas,  lym-
homas  and  hemangiomas.32 Nevertheless,  HCC  under  2  cm
n  a  cirrhotic  patient  still  poses  a  particular  diagnostic  chal-
enge,  owning  to  the  imaging  characteristics  of  the  cirrhotic
iver  background,1 and  reﬂects  the  pathological  morphol-
gy  progression  of  HCC.7 Early  HCC,  deﬁned  morphologically
s  malignant  nodules  with  indistinct  margins,20 reﬂects  a
ey  step  during  hepatocarcinogenesis.48 They  usually  mea-
ure  less  than  20  mm,  often  less  than  10  mm,  rarely  present
ith  vascular  invasion,  not  leading  to  intrahepatic  metas-
asis  and  solely  stromal  invasion  allows  the  differentiation
rom  dysplastic  nodules.7,49 Moreover,  unlike  advanced  HCC,
ascular  supply  of  early  HCC  is  driven  by  both  arterial  and
ortal  branches,7,32 but  because  the  tumoral  blood  ﬂow  is
till  largely  dependent  on  underdeveloped  neo-vessels,  such
esions  are  frequently  hypovascular.48 Other  characteristics
nclude  increased  cell  density,  increased  nuclear/cytoplasm
atio,  pseudoglandular  pattern  and  fatty  changes.46
A  prospective  study  including  89  cirrhotic  patients  with
iver  nodules  <20  mm  demonstrated  a  speciﬁcity  of  100%
hen  using  radiological  hallmarks  in  two  imaging  tech-
iques,  but  with  a  sensitivity  of  just  33%.2 Of  note,  the
peciﬁcity  when  using  isolated  MRI  was  just  below  97%,  with
 sensitivity  of  61.7%.  Another  prospective  study  found  sim-
lar  results;  using  a  step-wise  combination  of  the  different
on-invasive  modalities,  the  authors  concluded  that  a  sin-
le  imaging  technique  with  typical  HCC  pattern  allows  for  a
ertain  diagnosis  of  HCC  (no  false  positive  results)  and  with sensitivity  of  65%,  signiﬁcantly  superior  to  a  dual  positive
xamination  (p  =  0.028).50 These  results  underlined  the  fact
hat  while  the  typical  vascular  pattern  permits  a  safe  diag-
osis  of  HCC,  the  low  sensitivity  of  these  procedures  mean
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that  the  absence  of  radiological  hallmarks  in  these  patients
should  not  lead  to  the  exclusion  of  malignancy.
A  recent  study  showed  a  10%  false  positive  result  for
HCC  when  using  MRI  alone.51 Moreover,  local  disparities
in  expertise  and  suboptimal  equipment  may  worsen  the
diagnostic  accuracy  of  a  single  technique,  and  the  risk  of
frequent  false  positive  results  led  to  the  recommendation
of  two  concurrent  positive  radiological  hallmarks,  with  one
technique  being  sufﬁcient  in  excellence  centres  with  high-
end  radiological  equipment.5 Finally,  it  has  been  estimated
that  15%  of  patients  with  HCC,  in  particular  early-HCC,
will  not  present  with  the  radiological  hallmarks  of  arterial
enhancement  and  washout.2 When  imaging  characteristics
are  insufﬁcient  to  establish  the  diagnosis  of  HCC,  biopsy  may
o
i
7
h
Figure  4  HCC  during  dynamic  MRI  (arrow):  T1  weighted  scan  (a),  T
phase (d).arterial  phase  (a)  and  portal  phase  (b).
lso  be  required  to  distinguish  early-HCC  from  high-grade
ysplastic  nodules.  In  a  landmark  study  by  Forner  et  al.,2
on-invasive  HCC  diagnosis  (using  a  combination  of  dynamic
RI  plus  CEUS)  achieved  a  sensitivity  of  33%  and  a  speci-
city  of  100%,  and  subsequent  follow-up  biopsies  led  to  the
iagnosis  in  the  remaining  patients.
A  consensus  conference  on  pathology  for  hepatobiliary
alignancies  recommended  core  biopsies  over  ﬁne-needle
spiration  as  it  allows  for  the  assessment  of  both  architec-
ural  and  cytological  features.31 The  diagnostic  capability
f  liver  biopsy  may  be  further  ampliﬁed  by  the  use  of  an
mmunohistochemistry  panel  (glypican  3,  heat  shock  protein
0,  glutamine  synthetase,  cytokeratin  and  enhancer  of  zeste
omologue  2),46,52,53 as  the  combination  of  these  markers  has
2  weighted  scan  (b),  dynamic  arterial  phase  (c),  dynamic  late
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158  
hown  promising  results  in  the  diagnosis  of  early-HCC  ver-
us  dysplastic  nodules  in  prospective  studies.52,53 The  use  of
he  coaxial  biopsy  technique,  in  which  the  actual  needle  is
ntroduced  percutaneously  into  the  tumour  inside  a  sheath,
an  mitigate  the  risk  of  tumour  seeding  by  insulating  the
eedle  inside  the  sheath.1
Contrarily  to  smaller  nodules,  the  non-invasive  diagnosis
f  liver  nodules  >2  cm  is  very  effective,  as  the  accuracy  for
CC  diagnosis  using  either  dynamic  CT  or  MRI  is  over  90%.43
herefore,  radiological  hallmarks  in  a  single  technique  are
ufﬁcient  for  the  diagnosis  of  lesions  >2  cm.5
. Dynamic CT versus dynamic MRI
hen  comparing  dynamic  MRI  and  dynamic  CT,  sev-
ral  studies  compared  either  one  with  histology  as  gold
tandard.54,55
Diagnostic  accuracy  for  hypervascular  HCC  using  dynamic
T  is  reported  to  be  61--83%,56,57 compared  to  71--87%  in
ynamic  MRI.58--60 In  direct  comparison  studies,  the  latter
as  shown  to  be  superior  for  HCC  diagnosis  (sensitivity  76.9%
s  53.8%),61 while  the  results  were  conﬂicting  for  the  recur-
ence  of  HCC  following  arterial  chemoembolization.58,62,63
ost  studies  however  are  limited  by  selection  bias,
on-blindness  and  potential  for  generalization  for  all
entres.54,55 Therefore,  the  decision  to  use  either  MRI  or  CT
hould  be  based  on  local  expertise  and  equipment.
With  the  recent  advent  of  Gd-EOB-DTPA  MRI,  this  real-
ty  may  change  soon.  In  fact,  in  a  large  study  including
63  patients  and  comparing  Gd-EOB-DTPA  MRI  with  dynamic
RI,  dynamic  CT  and  US,  diagnostic  accuracy  with  the  for-
er  was  90%43 for  lesions  1--2  cm,  signiﬁcantly  superior
p  < 0.001)  to  dynamic  MRI  (84%),  dynamic  CT  (79%)  and  US
64%).43
The  superiority  of  Gd-EOB-DTPA  MRI  was  demonstrated  by
ther  authors,  displaying  diagnostic  accuracy  approaching
0%,  when  compared  to  standard  dynamic  MRI  (accuracy
1--87%)  and  CT  (accuracy  61--83%).58--60
However,  the  differential  diagnosis  between  early-HCC
nd  dysplastic  nodule  remains  to  be  difﬁcult,  and  some
arly-HCC  present  with  isointense  contrast  uptake  dur-
ng  the  postvascular  phase,  while  some  dysplastic  nodules
resent  with  low-intense  contrast  enhancing.7
. HCC in the non-cirrhotic liver
urrent  diagnostic  criteria  for  HCC  are  approved  only  for  a
irrhotic  liver  background,5 but  up  to  10%  of  the  HCC  may
e  diagnosed  in  a  healthy  liver64 or  in  the  setting  of  non-
lcoholic  fatty  liver  disease65 or  hepatitis  B  virus  infection.1
ew  studies  have  reported  on  the  imaging  characteristics
f  HCC  in  a  non-cirrhotic  liver,64,66,67 but  most  report  on
 higher  frequency  of  an  isolated  large  mass  when  com-
ared  to  HCC  in  the  cirrhotic  liver.  The  applicability  of
on-invasive  diagnostic  criteria  to  such  patients  has  been
et  with  disappointing  results.68 A  recent  study  with  32
atients,67 however,  has  shown  HCC  to  have  the  same  con-
rasting  enhancement  in  both  the  cirrhotic  and  non-cirrhotic
iver,  and  diagnostic  criteria  were  encountered  in  more  than
0%  of  the  patients,  and  the  authors  suggest  extending  such
riteria  to  the  non-cirrhotic  liver.
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